These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35079034)

  • 21. A novel nuclear factor-kappaB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status.
    Lee TL; Yang XP; Yan B; Friedman J; Duggal P; Bagain L; Dong G; Yeh NT; Wang J; Zhou J; Elkahloun A; Van Waes C; Chen Z
    Clin Cancer Res; 2007 Oct; 13(19):5680-91. PubMed ID: 17908957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling.
    Chiaretti S; Tavolaro S; Marinelli M; Messina M; Del Giudice I; Mauro FR; Santangelo S; Piciocchi A; Peragine N; Truong S; Patten N; Ghia EM; Torrente I; De Propris MS; Nanni M; Lawrence J; Guarini A; Foà R
    Genes Chromosomes Cancer; 2011 Apr; 50(4):263-74. PubMed ID: 21319261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic analysis of genotype-specific drug responses in cancer.
    Kim N; He N; Kim C; Zhang F; Lu Y; Yu Q; Stemke-Hale K; Greshock J; Wooster R; Yoon S; Mills GB
    Int J Cancer; 2012 Nov; 131(10):2456-64. PubMed ID: 22422301
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of genetic instability by gain-of-function p53 cancer mutants.
    Xu Y
    Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers.
    Hancock BA; Chen YH; Solzak JP; Ahmad MN; Wedge DC; Brinza D; Scafe C; Veitch J; Gottimukkala R; Short W; Atale RV; Ivan M; Badve SS; Schneider BP; Lu X; Miller KD; Radovich M
    Breast Cancer Res; 2019 Aug; 21(1):87. PubMed ID: 31383035
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TP53 tumor-suppressor gene and human carcinogenesis.
    Basset-Séguin N; Molès JP; Mils V; Dereure O; Guilhou JJ
    Exp Dermatol; 1993 Jun; 2(3):99-105. PubMed ID: 8162331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TP53 mutations and survival in squamous-cell carcinoma of the head and neck.
    Poeta ML; Manola J; Goldwasser MA; Forastiere A; Benoit N; Califano JA; Ridge JA; Goodwin J; Kenady D; Saunders J; Westra W; Sidransky D; Koch WM
    N Engl J Med; 2007 Dec; 357(25):2552-61. PubMed ID: 18094376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
    Knappskog S; Chrisanthar R; Løkkevik E; Anker G; Østenstad B; Lundgren S; Risberg T; Mjaaland I; Leirvaag B; Miletic H; Lønning PE
    Breast Cancer Res; 2012 Mar; 14(2):R47. PubMed ID: 22420423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress.
    Zhu KL; Su F; Yang JR; Xiao RW; Wu RY; Cao MY; Ling XL; Zhang T
    Mol Biol Rep; 2024 Jan; 51(1):205. PubMed ID: 38270700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.
    Neskey DM; Osman AA; Ow TJ; Katsonis P; McDonald T; Hicks SC; Hsu TK; Pickering CR; Ward A; Patel A; Yordy JS; Skinner HD; Giri U; Sano D; Story MD; Beadle BM; El-Naggar AK; Kies MS; William WN; Caulin C; Frederick M; Kimmel M; Myers JN; Lichtarge O
    Cancer Res; 2015 Apr; 75(7):1527-36. PubMed ID: 25634208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.
    Watanabe G; Ishida T; Furuta A; Takahashi S; Watanabe M; Nakata H; Kato S; Ishioka C; Ohuchi N
    Am J Surg Pathol; 2015 Aug; 39(8):1026-34. PubMed ID: 26171916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
    Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
    Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
    Ooe A; Kato K; Noguchi S
    Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.
    Miller LD; Smeds J; George J; Vega VB; Vergara L; Ploner A; Pawitan Y; Hall P; Klaar S; Liu ET; Bergh J
    Proc Natl Acad Sci U S A; 2005 Sep; 102(38):13550-5. PubMed ID: 16141321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant P53 in the formation and progression of the tumor microenvironment: Friend or foe.
    Asl ER; Rostamzadeh D; Duijf PHG; Mafi S; Mansoori B; Barati S; Cho WC; Mansoori B
    Life Sci; 2023 Feb; 315():121361. PubMed ID: 36608871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant p53 gain-of-function in cancer.
    Oren M; Rotter V
    Cold Spring Harb Perspect Biol; 2010 Feb; 2(2):a001107. PubMed ID: 20182618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
    El Baroudi M; Machiels JP; Schmitz S
    Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival.
    Bartel F; Jung J; Böhnke A; Gradhand E; Zeng K; Thomssen C; Hauptmann S
    Clin Cancer Res; 2008 Jan; 14(1):89-96. PubMed ID: 18172257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.